Literature DB >> 18606840

Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

Jesús Guinea1, Sandra Recio, Teresa Peláez, Marta Torres-Narbona, Emilio Bouza.   

Abstract

We studied the activity of voriconazole against 400 clinical strains of Aspergillus from the pre-voriconazole (1999 to 2002) and post-voriconazole (2003 to 2007) periods. Although the mean MICs of strains from the post-voriconazole period were slightly higher (0.39 versus 0.57 microg/ml; P < 0.001), all strains were susceptible to voriconazole and presented an MIC of <or=2 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18606840      PMCID： PMC2533497          DOI： 10.1128/AAC.00629-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

Authors:  E K Manavathu; J L Cutright; D Loebenberg; P H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Anthonius J M M Rijs; Hilly G De Vries-Hospers; Jacques F G M Meis
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  Multiple-triazole-resistant aspergillosis.

Authors:  Paul E Verweij; Emilia Mellado; Willem J G Melchers
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

4.  A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

Authors:  E Mellado; G Garcia-Effron; L Alcázar-Fuoli; W J G Melchers; P E Verweij; M Cuenca-Estrella; J L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

5.  In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.

Authors:  E Dannaoui; F Persat; M F Monier; E Borel; M A Piens; S Picot
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

6.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

7.  In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole.

Authors:  E Chryssanthou
Journal:  Scand J Infect Dis       Date:  1997

8.  Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.

Authors:  Eric Dannaoui; Joseph Meletiadis; Anna-Maria Tortorano; Françoise Symoens; Nicole Nolard; Maria-Anna Viviani; Marie-Antoinette Piens; Bernadette Lebeau; Paul E Verweij; Renée Grillot
Journal:  J Med Microbiol       Date:  2004-02       Impact factor: 2.472

9.  Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals.

Authors:  S Arunmozhi Balajee; Molly Weaver; Alexander Imhof; Jennifer Gribskov; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938
View more
  9 in total

1.  Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece.

Authors:  Michael Arabatzis; Manousos Kambouris; Miltiades Kyprianou; Aikaterini Chrysaki; Maria Foustoukou; Maria Kanellopoulou; Lydia Kondyli; Georgia Kouppari; Chrysa Koutsia-Karouzou; Evangelia Lebessi; Anastasia Pangalis; Efthimia Petinaki; Ageliki Stathi; Eleftheria Trikka-Graphakos; Erriketi Vartzioti; Aliki Vogiatzi; Timoleon-Achilleas Vyzantiadis; Loukia Zerva; Aristea Velegraki
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings.

Authors:  Roberta Iatta; Federica Nuccio; Davide Immediato; Adriana Mosca; Carmela De Carlo; Giuseppe Miragliotta; Antonio Parisi; Giuseppe Crescenzo; Domenico Otranto; Claudia Cafarchia
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

3.  Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.

Authors:  Claire M Martel; Josie E Parker; Andrew G S Warrilow; Nicola J Rolley; Steven L Kelly; Diane E Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

4.  Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene.

Authors:  Shawn R Lockhart; João P Frade; Kizee A Etienne; Michael A Pfaller; Daniel J Diekema; S Arunmozhi Balajee
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

5.  Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole.

Authors:  Pilar Escribano; Sandra Recio; Teresa Peláez; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

6.  Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus.

Authors:  Masato Tashiro; Koichi Izumikawa; Katsuji Hirano; Shotaro Ide; Tomo Mihara; Naoki Hosogaya; Takahiro Takazono; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Tomoya Nishino; Misuzu Tsukamoto; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Akira Yasuoka; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

7.  Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

Authors:  M A Pfaller; D J Diekema; M A Ghannoum; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; A Espinel-Ingroff; C L Fowler; E M Johnson; C C Knapp; M R Motyl; L Ostrosky-Zeichner; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

8.  Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Authors:  John W Baddley; Kieren A Marr; David R Andes; Thomas J Walsh; Carol A Kauffman; Dimitrios P Kontoyiannis; James I Ito; S Arunmozhi Balajee; Peter G Pappas; Stephen A Moser
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

Review 9.  Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature.

Authors:  A Mayr; Cornelia Lass-Flörl
Journal:  Eur J Med Res       Date:  2011-04-28       Impact factor: 2.175
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.